The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1

Steven P. O'Hara, Patrick L. Splinter, Christy E. Trussoni, Maria Eugenia Guicciardi, Noah P. Splinter, Mohammed S. Al Suraih, Navine Nasser-Ghodsi, Deborah Stollenwerk, Gregory J. Gores, Nicholas F. LaRusso

Research output: Contribution to journalArticle

Abstract

Primary sclerosing cholangitis (PSC) is an idiopathic, progressive cholangiopathy. Cholangiocyte senescence is important in PSC pathogenesis, and we have previously reported that senescence is regulated by the transcription factor ETS protooncogene 1 (ETS1) and associated with overexpression of BCL2 like 1 (BCL2L1 or BCL-xL), an anti-apoptotic BCL2-family member. Here, we further explored the mechanisms regulating BCL-xL-mediated, apoptosis resistance in senescent cholangiocytes and uncovered that ETS1 and the histone acetyltransferase E1A-binding protein P300 (EP300 or p300) both promote BCL-xL transcription. Using immunofluorescence, we found that BCL-xL protein expression is increased both in cholangiocytes of livers from individuals with PSC and a mouse model of PSC. Using an in vitro model of lipopolysaccharide-induced senescence in normal human cholangiocytes (NHCs), we found increased BCL-xL mRNA and protein levels, and ChIP-PCRs indicated increased occupancy of ETS1, p300, and histone 3 Lys-27 acetylation (H3K27Ac) at the BCL-xL promoter. Using co-immunoprecipitation and proximity ligation assays, we further demonstrate that ETS1 and p300 physically interact in senescent but not control NHCs. Additionally, mutagenesis of predicted ETS1-binding sites within the BCL-xL promoter blocked luciferase reporter activity, and CRISPR/Cas9-mediated genetic deletion of ETS1 reduced senescence-associated BCL-xL expression. In senescent NHCs, TRAIL-mediated apoptosis was reduced ~70%, and ETS1 deletion or RNAi-mediated BCL-xL suppression increased apoptosis. Overall, our results suggest that ETS1 and p300 promote senescent cholangiocyte resistance to apoptosis by modifying chromatin and inducing BCL-xL expression. These findings reveal ETS1 as a central regulator of both cholangiocyte senescence and the associated apoptosis-resistant phenotype.

Original languageEnglish (US)
Pages (from-to)18698-18713
Number of pages16
JournalJournal of Biological Chemistry
Volume294
Issue number49
DOIs
StatePublished - Jan 1 2019

Fingerprint

Sclerosing Cholangitis
Transcription Factors
Apoptosis
Clustered Regularly Interspaced Short Palindromic Repeats
Acetylation
Mutagenesis
Transcription
RNA Interference
Luciferases
Immunoprecipitation
Liver
Histones
Chromatin
Fluorescent Antibody Technique
Ligation
Lipopolysaccharides
Assays
Carrier Proteins
Proteins
Binding Sites

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. / O'Hara, Steven P.; Splinter, Patrick L.; Trussoni, Christy E.; Guicciardi, Maria Eugenia; Splinter, Noah P.; Al Suraih, Mohammed S.; Nasser-Ghodsi, Navine; Stollenwerk, Deborah; Gores, Gregory J.; LaRusso, Nicholas F.

In: Journal of Biological Chemistry, Vol. 294, No. 49, 01.01.2019, p. 18698-18713.

Research output: Contribution to journalArticle

O'Hara, SP, Splinter, PL, Trussoni, CE, Guicciardi, ME, Splinter, NP, Al Suraih, MS, Nasser-Ghodsi, N, Stollenwerk, D, Gores, GJ & LaRusso, NF 2019, 'The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1', Journal of Biological Chemistry, vol. 294, no. 49, pp. 18698-18713. https://doi.org/10.1074/jbc.RA119.010176
O'Hara, Steven P. ; Splinter, Patrick L. ; Trussoni, Christy E. ; Guicciardi, Maria Eugenia ; Splinter, Noah P. ; Al Suraih, Mohammed S. ; Nasser-Ghodsi, Navine ; Stollenwerk, Deborah ; Gores, Gregory J. ; LaRusso, Nicholas F. / The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. In: Journal of Biological Chemistry. 2019 ; Vol. 294, No. 49. pp. 18698-18713.
@article{45bd0381d27f42b9a930e3ebd83d50d5,
title = "The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1",
abstract = "Primary sclerosing cholangitis (PSC) is an idiopathic, progressive cholangiopathy. Cholangiocyte senescence is important in PSC pathogenesis, and we have previously reported that senescence is regulated by the transcription factor ETS protooncogene 1 (ETS1) and associated with overexpression of BCL2 like 1 (BCL2L1 or BCL-xL), an anti-apoptotic BCL2-family member. Here, we further explored the mechanisms regulating BCL-xL-mediated, apoptosis resistance in senescent cholangiocytes and uncovered that ETS1 and the histone acetyltransferase E1A-binding protein P300 (EP300 or p300) both promote BCL-xL transcription. Using immunofluorescence, we found that BCL-xL protein expression is increased both in cholangiocytes of livers from individuals with PSC and a mouse model of PSC. Using an in vitro model of lipopolysaccharide-induced senescence in normal human cholangiocytes (NHCs), we found increased BCL-xL mRNA and protein levels, and ChIP-PCRs indicated increased occupancy of ETS1, p300, and histone 3 Lys-27 acetylation (H3K27Ac) at the BCL-xL promoter. Using co-immunoprecipitation and proximity ligation assays, we further demonstrate that ETS1 and p300 physically interact in senescent but not control NHCs. Additionally, mutagenesis of predicted ETS1-binding sites within the BCL-xL promoter blocked luciferase reporter activity, and CRISPR/Cas9-mediated genetic deletion of ETS1 reduced senescence-associated BCL-xL expression. In senescent NHCs, TRAIL-mediated apoptosis was reduced ~70{\%}, and ETS1 deletion or RNAi-mediated BCL-xL suppression increased apoptosis. Overall, our results suggest that ETS1 and p300 promote senescent cholangiocyte resistance to apoptosis by modifying chromatin and inducing BCL-xL expression. These findings reveal ETS1 as a central regulator of both cholangiocyte senescence and the associated apoptosis-resistant phenotype.",
author = "O'Hara, {Steven P.} and Splinter, {Patrick L.} and Trussoni, {Christy E.} and Guicciardi, {Maria Eugenia} and Splinter, {Noah P.} and {Al Suraih}, {Mohammed S.} and Navine Nasser-Ghodsi and Deborah Stollenwerk and Gores, {Gregory J.} and LaRusso, {Nicholas F.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1074/jbc.RA119.010176",
language = "English (US)",
volume = "294",
pages = "18698--18713",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "49",

}

TY - JOUR

T1 - The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1

AU - O'Hara, Steven P.

AU - Splinter, Patrick L.

AU - Trussoni, Christy E.

AU - Guicciardi, Maria Eugenia

AU - Splinter, Noah P.

AU - Al Suraih, Mohammed S.

AU - Nasser-Ghodsi, Navine

AU - Stollenwerk, Deborah

AU - Gores, Gregory J.

AU - LaRusso, Nicholas F.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Primary sclerosing cholangitis (PSC) is an idiopathic, progressive cholangiopathy. Cholangiocyte senescence is important in PSC pathogenesis, and we have previously reported that senescence is regulated by the transcription factor ETS protooncogene 1 (ETS1) and associated with overexpression of BCL2 like 1 (BCL2L1 or BCL-xL), an anti-apoptotic BCL2-family member. Here, we further explored the mechanisms regulating BCL-xL-mediated, apoptosis resistance in senescent cholangiocytes and uncovered that ETS1 and the histone acetyltransferase E1A-binding protein P300 (EP300 or p300) both promote BCL-xL transcription. Using immunofluorescence, we found that BCL-xL protein expression is increased both in cholangiocytes of livers from individuals with PSC and a mouse model of PSC. Using an in vitro model of lipopolysaccharide-induced senescence in normal human cholangiocytes (NHCs), we found increased BCL-xL mRNA and protein levels, and ChIP-PCRs indicated increased occupancy of ETS1, p300, and histone 3 Lys-27 acetylation (H3K27Ac) at the BCL-xL promoter. Using co-immunoprecipitation and proximity ligation assays, we further demonstrate that ETS1 and p300 physically interact in senescent but not control NHCs. Additionally, mutagenesis of predicted ETS1-binding sites within the BCL-xL promoter blocked luciferase reporter activity, and CRISPR/Cas9-mediated genetic deletion of ETS1 reduced senescence-associated BCL-xL expression. In senescent NHCs, TRAIL-mediated apoptosis was reduced ~70%, and ETS1 deletion or RNAi-mediated BCL-xL suppression increased apoptosis. Overall, our results suggest that ETS1 and p300 promote senescent cholangiocyte resistance to apoptosis by modifying chromatin and inducing BCL-xL expression. These findings reveal ETS1 as a central regulator of both cholangiocyte senescence and the associated apoptosis-resistant phenotype.

AB - Primary sclerosing cholangitis (PSC) is an idiopathic, progressive cholangiopathy. Cholangiocyte senescence is important in PSC pathogenesis, and we have previously reported that senescence is regulated by the transcription factor ETS protooncogene 1 (ETS1) and associated with overexpression of BCL2 like 1 (BCL2L1 or BCL-xL), an anti-apoptotic BCL2-family member. Here, we further explored the mechanisms regulating BCL-xL-mediated, apoptosis resistance in senescent cholangiocytes and uncovered that ETS1 and the histone acetyltransferase E1A-binding protein P300 (EP300 or p300) both promote BCL-xL transcription. Using immunofluorescence, we found that BCL-xL protein expression is increased both in cholangiocytes of livers from individuals with PSC and a mouse model of PSC. Using an in vitro model of lipopolysaccharide-induced senescence in normal human cholangiocytes (NHCs), we found increased BCL-xL mRNA and protein levels, and ChIP-PCRs indicated increased occupancy of ETS1, p300, and histone 3 Lys-27 acetylation (H3K27Ac) at the BCL-xL promoter. Using co-immunoprecipitation and proximity ligation assays, we further demonstrate that ETS1 and p300 physically interact in senescent but not control NHCs. Additionally, mutagenesis of predicted ETS1-binding sites within the BCL-xL promoter blocked luciferase reporter activity, and CRISPR/Cas9-mediated genetic deletion of ETS1 reduced senescence-associated BCL-xL expression. In senescent NHCs, TRAIL-mediated apoptosis was reduced ~70%, and ETS1 deletion or RNAi-mediated BCL-xL suppression increased apoptosis. Overall, our results suggest that ETS1 and p300 promote senescent cholangiocyte resistance to apoptosis by modifying chromatin and inducing BCL-xL expression. These findings reveal ETS1 as a central regulator of both cholangiocyte senescence and the associated apoptosis-resistant phenotype.

UR - http://www.scopus.com/inward/record.url?scp=85076325559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076325559&partnerID=8YFLogxK

U2 - 10.1074/jbc.RA119.010176

DO - 10.1074/jbc.RA119.010176

M3 - Article

C2 - 31659122

AN - SCOPUS:85076325559

VL - 294

SP - 18698

EP - 18713

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 49

ER -